various biological roles, including transepithelial transporting fluids and nutrients, constituting the outer blood-retinal barrier, phagocytosing photoreceptor outer segment tips, and recycling bleached visual pigments. [1] Therefore, RPE dysfunction could contribute to various ocular disorders accompanied by visual impairment and even blindness, most notably age-related macular degeneration (AMD). [2] Currently, the global prevalence of AMD in individuals aged 45 years and older is ≈8.7%. [3] Regarding AMD therapeutic options, the current anti-vascular therapeutic is limited for patients with neovascular AMD, whereas nearly no satisfactory strategies were available for non-neovascular AMD, which drives an urgent requirement to improve treatments among AMD patients. [4] The explicit etiology during the progression of AMD is not thoroughly understood. However, it has been generally accepted that detrimental oxidative stress in metabolically active RPE exerts a causative, primary impact on increased RPE vulnerability and subsequent photoreceptor cell degeneration, ultimately causing impairment of central vision or blindness. [5] Ferrous ions, as a typical source of oxidative stress, have been widely implicated in the progression of AMD. [6] In contrast to the age-matched healthy macula, higher levels of total iron in RPE cells in addition to in Bruch's membrane have been measured in the AMD-affected maculae, [7] and a more than twofold increase in iron concentration was detected in the aqueous humor of dry AMD. [8] Additionally, the excessive iron released from intraocular hemorrhage induces retinal inflammation and peroxidation of unsaturated phospholipids. [9] These studies have shown that iron toxicity and oxidative stress are closely associated with RPE death during AMD progression, suggesting that highly effective ferrous reduction provides a better platform to manage these diseases. Deferoxamine (DFO) is a typical type of iron chelator, yet it can be readily eliminated, with a plasma t 1/2 of ≈5-10 min, after intravenous injection in human subjects. [10] In addition, DFO mainly accumulates in lysosomes, [11] and protects against cells merely by chelating lysosomal iron. [12] However, iron accumulation in the RPE also involves a disruption of mitochondrial iron homeostasis, [13] implicating the limited effects of DFO on alleviating iron overload and oxidative stress-induced RPE damage. Inspiringly, it has been demonstrated that the potent Ca 2+ -substituted iron-binding Prussian blue analogue KCa[Fe III (CN) 6 ] (CaPB) can enter bacterial cells and selectively deplete intracellular iron by a simplistic Lethal oxidative stress and ferrous ion accumulation-mediated degeneration/ death in retinal pigment epithelium (RPE) exert an indispensable impact on retinal degenerative diseases with irreversible visual impairment, especially in age-related macular degeneration (AMD), but corresponding pathogenesisoriented medical intervention remains controversial. In this study, the potent iron-binding nanoscale Prussia...